A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease

CLINICAL OPHTHALMOLOGY (September 2021)
David McMullin, David Clark, Bill Cavanagh, Paul Karpecki, Todd C Brady